Novartis 2nd-qtr sales and net profit up but miss analysts’ forecasts
Switzerland’s Novartis (NOVN: VX) – now the world’s largest pharmaceutical company by sales - this morning posted financial results for the second quarter of 2014, showing that net sales of $14.6 billion grew 2% (+2% at constant exchange rates, missing analysts’ forecasts of $14.76 billion, and strong operating income growth of 6% (+11% cc) growing faster than sales.
Net profit attributable to shareholders rose 1.6% to $2.56 billion, also missing forecasts of $2.6 billion. Earnings excluding some items increased 3 % to $3.28 billion, or $1.34 a share, falling slightly short of the average estimate of $1.37 a share among 11 analysts compiled by Bloomberg.
Maintains previous guidance
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze